Adamas Pharmaceuticals, Inc. (ADMS) News
Filter ADMS News Items
ADMS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADMS News Highlights
- For ADMS, its 30 day story count is now at 12.
- Over the past 23 days, the trend for ADMS's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- LAW, ACT and SUPN are the most mentioned tickers in articles about ADMS.
Latest ADMS News From Around the Web
Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.
Supernus Pharmaceuticals Completes Acquisition of Adamas PharmaceuticalsAcquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flowROCKVILLE, Md., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that it has successfully completed its previously announced acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). “Adamas fits squarely within our corporate development strategy, adding a late-stage commercial product with significant revenue,” said Jack Khattar, President and CEO of Supern |
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender OfferROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus’ proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021. On October 21, 2021, Supernus and Adamas filed the Premerger Notification and Report Forms required under the HSR Act with the Federal Trade Com |
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerNEW YORK, NY / ACCESSWIRE / November 12, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) relating to its proposed acquisition by Supernus Pharmaceuticals, Inc. |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP is Investigating the Following Companies - BCML, GWB, ABTX, ESBK, ADMS, ACBIHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, ADMS, and ACBI Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ROG, RRD, XLRN, ADMS; Shareholders are Encouraged to Contact the FirmHalper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: |
Supernus Pharmaceuticals, inc (SUPN) Q3 2021 Earnings Call TranscriptGood afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' Third Quarter 2021 Financial Results Conference Call. On the call with me today are Supernus' Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Tim Dec. Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds OMP, ADMS, ACBI and ECHO Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
ADAMAS PHARMACEUTICALS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adamas Pharmaceuticals, Inc. - ADMSFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, shareholders of Adamas will receive only $8.10 in cash and two non-tradable contingent value rights (CVR) collectively worth up to $1.00 per share in cash (assuming certain conditions are met) for each s |
How Much Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Do Institutions Own?If you want to know who really controls Adamas Pharmaceuticals, Inc. ( NASDAQ:ADMS ), then you'll have to look at the... |